Evaluation of Trimethylamine N-oxide (TMAO) Levels in Periodontal Disease

Ankara Medipol University

Status

Completed

Conditions

Periodontitis

Inflammation

Trimethylamine N-oxide (TMAO)

TNF-alfa

Treatments

Diagnostic Test: Salivary and Serum TNF-α Mesurement

Diagnostic Test: Salivary and Serum TMAO Mesurement

Study type

Observational

Funder types

Other

Identifiers

NCT06906510

1004

Details and patient eligibility

About

Salivary and serum levels of TMAO and TNF-α can distinguish between individuals with periodontitis and periodontally healthy individuals.

Full description

Trimethylamine N-oxide (TMAO), a gut flora-derived metabolite from dietary choline, has emerged as an indicator of atherosclerosis. Circulatory TMAO has been implicated in cardiovascular risks by altering enterohepatic cholesterol and bile acid metabolism, increasing macrophage scavenger receptor expression, and activating nuclear factor kappa B (NF-κB) via pro-inflammatory genes such as interleukin-1 (IL-1). The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), which plays a crucial role in immune responses and inflammation, has been demonstrated as a crucial participant also during the development of periodontal diseases. The aim of this study is to evaluate difference in salivary and serum levels of TMAO and TNF-α between individuals with periodontitis and periodontally healthy individuals.

The study includes two groups: systemically and periodontally healthy control subjects (n= 24), and patients with periodontitis (n=24). Periodontal parameters were recorded. TMAO levels in saliva and serum were determined by liquid chromatography-mass spectrometry (LC-MS/MS), and TNF-α levels were determined by ELISA.

Enrollment

48 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

being over 18 and under 65 years of age;
having at least 20 natural teeth excluding the third molars; and
being systemically healthy.

Exclusion criteria

being smoker;
chronic use of any systemic medication
use of antibiotics and/or anti-inflammatory steroids, nonsteroidal anti-inflammatory drugs, immunosuppressants, beta-blockers, calcium channel blockers, anticoagulants, or hormonal contraceptives within 3 months preceding the study;
pregnancy or lactation; and
use of orthodontic appliances